Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4

Core Insights - Allogene Therapeutics (ALLO) reported a narrower fourth-quarter 2025 loss of 17 cents per share, compared to the Zacks Consensus Estimate of a loss of 25 cents and a loss of 28 cents in the same quarter last year [1][5] - The company's shares have increased by 80% year-to-date, significantly outperforming the industry average growth of 4% [1] Financial Performance - Research and development (R&D) expenses for Q4 2025 were $28.6 million, a decrease of 36% from the previous year [3] - General and administrative (G&A) expenses fell by 11% year-over-year to $13.8 million [3] - Allogene ended 2025 with $258.3 million in cash and cash equivalents, down from $277 million as of September 30, 2025, which is expected to fund operations into the first quarter of 2028 [3] Annual Results - For the full year 2025, Allogene did not record any revenues and reported a loss of 87 cents per share, an improvement from the loss of $1.32 per share in the previous year [4] 2026 Guidance - The company anticipates full-year operating expenses to be around $210 million, including nearly $35 million in non-cash stock-based compensation [6] - Cash burn for the full year is expected to be approximately $150 million [6] Pipeline Updates - Allogene's primary focus is on the pivotal phase II ALPHA3 study evaluating cema-cel for treating newly diagnosed large B-cell lymphoma patients, with data expected in April 2026 [7] - The company has initiated the phase I RESOLUTION basket study for ALLO-329 in various autoimmune diseases, with initial data expected in June 2026 [8] - Allogene is also developing ALLO-316, currently in the phase I TRAVERSE study for advanced renal cell carcinoma, and is exploring partnership opportunities for its development [9]